Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2013; 19(35): 5837-5847
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5837
Published online Sep 21, 2013. doi: 10.3748/wjg.v19.i35.5837
Table 1 Demographic and baseline characteristics of the safety and efficacy phase
| Safety phase | Efficacy phase | ||
| Gluten + AN-PEP | Gluten + placebo | Gluten + AN-PEP | |
| (n = 16) | (n = 7) | (n = 7) | |
| Patients (n) | 16 | 7 | 7 |
| Gender (female:male) | 12:4 | 5:2 | 6:1 |
| Median age at inclusion, yr (range) | 55 (20-68) | 44 (20-68) | 57 (30-64) |
| Median age at diagnosis, yr (range) | 44.5 (0-62) | 29 (0-62) | 49 (26-53) |
| Median time on a GFD, yr (range) | 7.5 (2-40) | 9 (2-40) | 8 (4-12) |
| HLA class (n) | |||
| DQ2/X | 12 | 5 | 5 |
| DQ2/DQ2 | 2 | 1 | 1 |
| DQ2/DQ8 | 1 | 0 | 1 |
| Unknown | 1 | 1 | 0 |
| Marsh at inclusion (n) | |||
| Marsh 0 | 10 | 4 | 3 |
| Marsh I | 6 | 3 | 4 |
| Gastrointestinal symptoms | |||
| Abnormal bowel sounds | 4 | 0 | 2 |
| Abdominal pain | 5 | 3 | 2 |
| Bowel distension | 5 | 3 | 1 |
| Change of defecation | 4 | 2 | 6 |
| Constipation | 3 | 2 | 0 |
| Diarrhoea | 3 | 1 | 1 |
| Dysgeusia | 1 | 1 | 0 |
| Flatulence | 6 | 1 | 2 |
| Nausea | 4 | 2 | 0 |
| Reflux | 2 | 0 | 1 |
| Vomiting | 1 | 1 | 0 |
| Weight loss | 0 | 1 | 0 |
| Total number of symptoms | 38 | 17 | 15 |
- Citation: Tack GJ, van de Water JM, Bruins MJ, Kooy-Winkelaar EM, van Bergen J, Bonnet P, Vreugdenhil AC, Korponay-Szabo I, Edens L, von Blomberg BME, Schreurs MW, Mulder CJ, Koning F. Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World J Gastroenterol 2013; 19(35): 5837-5847
- URL: https://www.wjgnet.com/1007-9327/full/v19/i35/5837.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i35.5837